OTTAWA, Canada and PALO ALTO, CA, October 4, 2006 - GangaGen, Inc., a biopharmaceutical company developing bacteriophage technology for the treatment of antibiotic resistant bacterial infections, announced today that it has received a new US patent. The patent is for the invention of “Lysin-deficient bacteriophages having reduced immunogenicity”, where they can be used to destroy pathogenic bacteria, including those resistant to antibiotics. The discovery strengthens the potential for the use of phages as a therapeutic drug against chronic bacterial infections.
The value of the new patent is that it creates the opportunity for phages to be used as a systemic therapeutic, that is, potentially as an injectable, in both human and veterinary medicine. This is in addition to the use of phage-based drugs as a topical antibacterial.
Bacteriophages or “phages” are naturally occurring agents that target and destroy bacteria with a high degree of efficiency, and do so selectively and specifically without affecting beneficial bacteria or tissue cells.
Natural lytic phages, found in the human and general environment, are not lysin-deficient. They infect target bacteria, make multiple copies of themselves, and then break out of the bacterial cell by perforating the cell wall, using an enzyme lysin produced by the phages themselves. This process effectively explodes the bacterial cell to release the new phages to infect other bacteria. As effective as phages are in killing bacteria, this creates a risk factor in that there is loss of control over treatment dose strength.
A further potential undesirable side effect, particularly when natural lytic phages are injected to combat infection, is the potential for immunogenic reactions in the patient by having large uncontrolled amounts of phages in circulation.
By contrast, GangaGen’s lysin-deficient phages do not release new phages from the killed bacteria, but still maintain their specificity and effectiveness in killing the pathogenic bacteria. Therefore, the pathogenic bacteria are killed effectively and are then removed from circulation by the body’s normal defense systems without secondary effects, such as immune reactions.
GangaGen has initiated proof-of-concept studies of lysin-deficient phages in animal trials. Early results show this to be effective in the treatment of acute systemic infection, and as a promising vaccine approach.
The new patent increases the portfolio of granted and filed patents held by GangaGen and its two affiliates, GangaGen Life Sciences Inc., Ottawa, Canada and GangaGen Biotechnologies Pvt Ltd., Bangalore, India. The invention arises from work carried out by the Bangalore company and lists Dr. Janakiraman Ramachandran, Sriram Padmanabhan and Bharati Sriram as co-inventors.
It supports two earlier GangaGen U.S. patents granted in 2005 that describe the novelty of generating lysin-deficient phages and using these as an effective anti-bacterial vaccine, as well as a direct-acting bactericidal therapeutic.
About GangaGen GangaGen, Inc. is an emerging biopharmaceutical company operating through two affiliate subsidiaries, GangaGen Biotechnologies Pvt Ltd, established in 2000 in Bangalore, India, and GangaGen Life Sciences, established in 2002 in Ottawa, Canada. The GangaGen group works closely together to develop modern bacteriophage-based products for the prevention and treatment of bacterial infections. The corporation has successfully developed cutting-edge patented intellectual property for a phage product pipeline to target bacterial diseases to both prevent and cure infections, including those resistant to antibiotics. The product pipeline targets bacterial infection issues in food safety and in human and animal medicine.
For further information or to arrange for interviews, please contact:
Linda Woods inmedia Public Relations Tel: (613) 234-7227 ext. 234 lwoods@inmedia.com or Danny Sullivan inmedia Public Relations Tel: (613) 686-5657 dsullivan@inmedia.com